Endoscopic Samples Show Precancerous Genomic Changes in Barrett's Esophagus
|
By LabMedica International staff writers Posted on 22 Jun 2015 |

Image: The Invitrogen Qubit Fluorometer for routine DNA, RNA, and protein quantitation (Photo courtesy of Life Technologies).
Next-generation sequencing (NGS) has been used to detect genomic mutations in precancerous esophageal tissue, which may improve cancer surveillance and early detection in patients with Barrett's esophagus.
Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus and although periodic surveillance for cancer is recommended for BE patients; these examinations may fail to identify precancerous dysplasia and early cancers.
Scientists at Columbia University College of Physicians and Surgeons (New York, NY, USA) and their colleagues selected two groups of patients: 13 "non-progressors" who were patients with BE who never manifested dysplasia or esophageal adenocarcinoma (EAC) during at least two years of monitoring, and 15 "progressors" who were patients who developed high-grade dysplasia (HGD) or EAC, and control samples showing no evidence of Barrett's intestinal metaplasia. The investigators analyzed formalin-fixed, paraffin-embedded (FFPE) tissue samples tissue taken from esophageal biopsies or endoscopic mucosal resections.
DNA was extracted and quantitated by fluorometry with the Invitrogen Qubit fluorometer and the Invitrogen Quant-iT double-strand DNA BR Assay Kit (Life Technologies; Grand Island, NY, USA). Samples from some patients were sequenced in either Life Technologies Ion Torrent and/or MiSeq (Illumina, San Diego, CA, USA) platforms, or in parallel.
The team found that found that progressors had mutations in 75% (6/8) of cases compared to 0% in non-progressors. The tumor suppressor protein p53 (TP53) was the most commonly mutated gene in the BE progressor group. Mutations were also found in the adenomatous polyposis coli (APC) and cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor suppressor genes. Next-generation sequencing from routine FFPE non-neoplastic Barrett’s esophagus samples can detect multiple mutations in minute areas of Barrett’s intestinal metaplasia (BIM) with high analytical sensitivity.
The authors concluded that that DNA from routine endoscopic FFPE samples of non-dysplastic BIM can be efficiently used to simultaneously detect multiple mutations by NGS with high analytical sensitivity, enabling the application of genomic testing of BE patients for improved HGD and EAC surveillance in clinical practice. Antonia R. Sepulveda, MD, PhD, Professor of Pathology and Cell Biology, and senior author of the study said, “The ability to detect mutations in non-neoplastic mucosa, quantitatively and with high detection sensitivity, makes it possible to use NGS mutational testing in the early detection and surveillance of patients who develop BE.” The study was published in the July 2015 issue of the Journal of Molecular Diagnostics.
Related Links:
Columbia University College of Physicians and Surgeons
Life Technologies
Illumina
Barrett's esophagus (BE) develops in a subset of patients with gastroesophageal reflux disease (GERD) and can increase the risk of developing cancer of the esophagus and although periodic surveillance for cancer is recommended for BE patients; these examinations may fail to identify precancerous dysplasia and early cancers.
Scientists at Columbia University College of Physicians and Surgeons (New York, NY, USA) and their colleagues selected two groups of patients: 13 "non-progressors" who were patients with BE who never manifested dysplasia or esophageal adenocarcinoma (EAC) during at least two years of monitoring, and 15 "progressors" who were patients who developed high-grade dysplasia (HGD) or EAC, and control samples showing no evidence of Barrett's intestinal metaplasia. The investigators analyzed formalin-fixed, paraffin-embedded (FFPE) tissue samples tissue taken from esophageal biopsies or endoscopic mucosal resections.
DNA was extracted and quantitated by fluorometry with the Invitrogen Qubit fluorometer and the Invitrogen Quant-iT double-strand DNA BR Assay Kit (Life Technologies; Grand Island, NY, USA). Samples from some patients were sequenced in either Life Technologies Ion Torrent and/or MiSeq (Illumina, San Diego, CA, USA) platforms, or in parallel.
The team found that found that progressors had mutations in 75% (6/8) of cases compared to 0% in non-progressors. The tumor suppressor protein p53 (TP53) was the most commonly mutated gene in the BE progressor group. Mutations were also found in the adenomatous polyposis coli (APC) and cyclin-dependent kinase inhibitor 2A (CDKN2A) tumor suppressor genes. Next-generation sequencing from routine FFPE non-neoplastic Barrett’s esophagus samples can detect multiple mutations in minute areas of Barrett’s intestinal metaplasia (BIM) with high analytical sensitivity.
The authors concluded that that DNA from routine endoscopic FFPE samples of non-dysplastic BIM can be efficiently used to simultaneously detect multiple mutations by NGS with high analytical sensitivity, enabling the application of genomic testing of BE patients for improved HGD and EAC surveillance in clinical practice. Antonia R. Sepulveda, MD, PhD, Professor of Pathology and Cell Biology, and senior author of the study said, “The ability to detect mutations in non-neoplastic mucosa, quantitatively and with high detection sensitivity, makes it possible to use NGS mutational testing in the early detection and surveillance of patients who develop BE.” The study was published in the July 2015 issue of the Journal of Molecular Diagnostics.
Related Links:
Columbia University College of Physicians and Surgeons
Life Technologies
Illumina
Latest Pathology News
- AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
- New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
- Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Channels
Clinical Chemistry
view channel
Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research
Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more
Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk
Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreImmunology
view channel
Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice
Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
New WHO Tools Address Gaps in Antimicrobial Resistance Testing
Antimicrobial resistance (AMR) is a growing global health threat, making infections increasingly difficult to diagnose and treat as they become resistant to standard antibiotics. Its spread is driven partly... Read more
Complete Malaria Genomes Could Improve Species Identification and Surveillance
Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read morePathology
view channel
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians
Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more







